Pacific Therapeutics Ltd. is a clinical stage specialty pharmaceutical company listed on the
Canadian National Stock Exchange (CNSX) under the symbol PT. The company is focused on
the identification and development of drug candidates to treat diseases of excessive scarring
(fibrosis) such as liver fibrosis and liver cirrhosis.
The company’s lead drug candidate PTL-202 is a combination of Pentoxifylline (a FDA
approved drug used for treating intermittent claudication) and N-Acetyl-Cysteine (NAC) an
amino acid and an extremely potent and important antioxidant. PTL-202 is currently being
reviewed for initial trials in humans which are expected to commence in 2012.
Pacific Therapeutics’ business and drug development strategy reduces risk, time and the capital
costs of developing new drug therapies for liver and lung diseases caused by fibrosis. By
combining existing approved drugs that have already known safety and toxicity profiles, the
company eliminates the inherent risks involved with basic pre clinical research and animal
PTL-202 is being developed by Pacific Therapeutics to treat a progressive lung scarring
disease, Idiopathic Pulmonary Fibrosis (IPF). More people die of annually IPF than either
prostate or breast cancer. IPF is estimated to be a $2 billion market opportunity.
On December 7, 2011 Pacific Therapeutics engaged CRBIO (Clinical Research and
Biosciences of Hyderabad, India to conduct a clinical trial with PTL-202 in
a drug to drug interaction study in humans. CRBIO is the clinical trials a division of RA Chem

For the formulated once a day tablets PTL-202, uses the multi-layer technology developed by
IntelGenx Corp. of Montreal. The multi-layer technology has been identified as an excellent fit
to provide different release profiles of the Active Ingredients, and establishing blood levels of the
Active Ingredients which is designed to maximize their efficacy.
Pacific Therapeutics’ second drug candidate, PTL-303, is also a combination of drugs, one of
which has been approved for human use in Japan. PTL-303 has been shown to be effective in
the reduction of molecules that contribute to the development of diseases including, liver
cirrhosis in humans. PTL-303 may be developed as a treatment to reduce the severity of
progressive diseases like chronic liver disease.
Chronic liver disease which may lead to cirrhosis of the liver is responsible for over 1.4m deaths
annually (WHO, World Health Report 2004) In the US chronic liver disease is among the top ten
disease related causes of death (CDC, National Center for Health Statistics, 2004). This market
is estimated to be $3.0 billion.
Share Capital - March 2012
Directors Officers and Senior Management
Symbol: PT.CNSX
Douglas H. Unwin, CEO & President
409 Granville Street Suite 1023, Vancouver, BC V6C 1T2  Certain statements included in this information constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This information contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Readers should not place undue reliance on the Company’s forward-looking statements, as the Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company’s business, or if the Company’s estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.


Contra-ideias :: crÍtica contemporÂnea 201

CONTRA-IDEIAS :: CRÍTICA CONTEMPORÂNEA Jaime Da Silva Lopes O voto da oposição-líder O líder da oposição não está preparado para assumir, e compensar, as clivagens irremediáveis que seriam as consequências do voto contra o Orçamento Os partidos vocacionados para o poder têm a tentação de não sair dessa 'zona de conforto' que é a participação governativa. Praticar

Microsoft word - hp用業績(more_.doc

Goto, G.H. Katayama, H. Tanigaki, Y. Fushiki, S. Nishizawa, Y and Nishizawa, Y. (2008) Methylcobalamin inhibits fibroblast growth factor-8 stimulated proliferation and induces apoptosis in Shionogi carcinoma cells. Int. J. Vitam. Nutr. Res., 78, 21-26 Kataoka, T. Tsukamoto, Y. Matsumura, M. Miyake, A. Kamiura, S. Ishiguro, S. and Nishizawa, Y. (2008) Expression of p21Cip1/Waf1 and p27Kip1 in s

Copyright © 2010-2014 Drug Shortages pdf